novartis

NeoPSMA: A Phase I/II, Open-label, Multi-center Study of Neoadjuvant Treatment With [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Adults With Prostate-specific Membrane Antigen (PSMA) Positive High-risk Localized Prostate Cancer (HRLPC) Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection

Description:

The purpose of this trial is to learn more about the effects of AAA602 and AAA802 in men with prostate-specific membrane antigen (PSMA) positive high-risk localized prostate cancer (HRLPC) before surgery to remove the prostate and lymph nodes present in the pelvis area. Lymph nodes are small structures near the prostate that help fight infections. These lymph nodes are removed during surgery because they are a site the disease can spread to.

Sponsor:

Novartis

Contacts:

Novartis Pharmaceuticals

novartis.email@novartis.com

1-888-669-6682

[177Lu]Lu-PSMA-R2 (AAA602)

Isotope(s):
Target(s):
  • PSMA

[225Ac]Ac-PSMA-R2 (AAA802)

Isotope(s):
Target(s):

Patient Education


Patient Education Not Yet Provided

Publications


Publications Not Yet Provided

Locations


Not yet provided. Contact Novartis Pharmaceuticals for more information.

1-888-669-6682

novartis.email@novartis.com

XCancer

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468